< clinical trials / ATORVO

Clinical Trial Name:
Atorvastatin Toronto Retinal Vein Occlusion (ATORVO) Study

Status: enrolling

Brief description:  
Phase III double blind, randomized clinical trial comparing high-dose Atorvastatin (80mg) daily vs. placebo in persons recently diagnosed with retinal vein occlusion. Study participants will be identified through ophthalmology practices across greater Toronto. Consenting individuals will be considered for enrolment, and enrolled, through St. Michael’s Hospital (SMH) Vitreo-Retinal Diseases Unit.

Main Study Outcome: Visual acuity at 24 weeks.

Eligibility:  
Adults aged 40 year and older. Diagnosed with central or branch retinal vein occlusion. Visual acuity of 20/40 or worse in the affected eye. Onset of loss of vision within the past 60 days.

Exclusion:
Current user of a statin or fibrate medication. Known cardiovascular disease (history of coronary artery disease or stroke). Known diabetes mellitus.

Sponsor(s):
Initiated by researchers at St.Michael's Hospital, Toronto, Ontario.
Funded by Pfizer Inc.

Contact:
Dr.  Joel G Ray, Department of Medicine, St. Michael’s Hospital,
30 Bond Street, Toronto, Ontario  M5B 1W8
--------------------------------------------------------------------------------------
Tel: (416) 864-6060, Ext 6752; Fax : (416) 864-5485; e-mail: rayj@smh.toronto.on.ca